Trials / Completed
CompletedNCT00434733
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,400 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pandemic influenza vaccine |
Timeline
- Start date
- 2007-01-01
- First posted
- 2007-02-13
- Last updated
- 2008-04-24
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT00434733. Inclusion in this directory is not an endorsement.